Idris Ab, Mahmoud Sm, S. MohamedElamin, Mustafa Yy, O. Aa, Adam Me, Ali Lb, Abbas Mh, Ahmed Hamdi Abu-haraz, K. A. Abd-elrahman, M. Salih
{"title":"从包膜糖蛋白和核衣壳蛋白中提取B细胞和t细胞表位的免疫信息学预测和建模","authors":"Idris Ab, Mahmoud Sm, S. MohamedElamin, Mustafa Yy, O. Aa, Adam Me, Ali Lb, Abbas Mh, Ahmed Hamdi Abu-haraz, K. A. Abd-elrahman, M. Salih","doi":"10.4172/1745-7580.1000141","DOIUrl":null,"url":null,"abstract":"Sin Nombre virus is a category A pathogen with a reported mortality rate ranging from 30% to 50%. It was responsible for the 2012 Yosemite National Park outbreak. Until now, Specific therapy is not available for the treatment of HCPS caused by SNV. Despite many efforts to develop safe and effective vaccines against SNV, included conventional approaches as well as molecular vaccine approaches, to date there are no vaccines proven to be highly efficacious against SNV. In our study, we analyzed envelope glycoprotein and nucleocapsid of SNV by using immunoinformatics tools housed in IEDB resources; in order to determine the most conserved and immunogenic epitopes for B- and T-cells. Then the predicted epitopes were assessed for the population coverage against the whole world population with the MHC-I and MHC-II restricted alleles. Among predicted epitopes for B-cell, the best candidates for glycoprotein and nucleocapsid were the epitope 743CKKYAYPWQT752 and the epitope 271QVDESKVS278, respectively. For glycoprotein CD8+ T cell predicted epitopes, the epitopes 208MTLPVTCFL216 and 458YTFTSLFSL466 were selected. Interestingly, the best candidates epitopes for nucleocapsid were the epitopes 25YILSFALPI133 and 239FLAARCPFL247 which had high affinity to interact with both MHC classes, I and II, and they had an excellent population coverage for Class I and II alleles throughout the world. To the best of our knowledge, our study for the first time has predicted a cocktail of B- and T-cell epitopes for designing an effective vaccine against HCPS caused by SNV","PeriodicalId":73347,"journal":{"name":"Immunome research","volume":"13 1","pages":"1-18"},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Immunoinformatics Predication and Modelling of a Cocktail of B- and T-cells Epitopes from Envelope Glycoprotein and Nucleocapsid Proteins of Sin Nombre Virus\",\"authors\":\"Idris Ab, Mahmoud Sm, S. MohamedElamin, Mustafa Yy, O. Aa, Adam Me, Ali Lb, Abbas Mh, Ahmed Hamdi Abu-haraz, K. A. Abd-elrahman, M. Salih\",\"doi\":\"10.4172/1745-7580.1000141\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Sin Nombre virus is a category A pathogen with a reported mortality rate ranging from 30% to 50%. It was responsible for the 2012 Yosemite National Park outbreak. Until now, Specific therapy is not available for the treatment of HCPS caused by SNV. Despite many efforts to develop safe and effective vaccines against SNV, included conventional approaches as well as molecular vaccine approaches, to date there are no vaccines proven to be highly efficacious against SNV. In our study, we analyzed envelope glycoprotein and nucleocapsid of SNV by using immunoinformatics tools housed in IEDB resources; in order to determine the most conserved and immunogenic epitopes for B- and T-cells. Then the predicted epitopes were assessed for the population coverage against the whole world population with the MHC-I and MHC-II restricted alleles. Among predicted epitopes for B-cell, the best candidates for glycoprotein and nucleocapsid were the epitope 743CKKYAYPWQT752 and the epitope 271QVDESKVS278, respectively. For glycoprotein CD8+ T cell predicted epitopes, the epitopes 208MTLPVTCFL216 and 458YTFTSLFSL466 were selected. Interestingly, the best candidates epitopes for nucleocapsid were the epitopes 25YILSFALPI133 and 239FLAARCPFL247 which had high affinity to interact with both MHC classes, I and II, and they had an excellent population coverage for Class I and II alleles throughout the world. To the best of our knowledge, our study for the first time has predicted a cocktail of B- and T-cell epitopes for designing an effective vaccine against HCPS caused by SNV\",\"PeriodicalId\":73347,\"journal\":{\"name\":\"Immunome research\",\"volume\":\"13 1\",\"pages\":\"1-18\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immunome research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4172/1745-7580.1000141\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunome research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/1745-7580.1000141","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
摘要
Sin Nombre病毒是一种a类病原体,据报告死亡率在30%至50%之间。它是2012年约塞米蒂国家公园爆发的罪魁祸首。到目前为止,还没有针对SNV引起的HCPS的特异性治疗方法。尽管在开发安全有效的SNV疫苗方面作出了许多努力,包括常规方法和分子疫苗方法,但迄今为止,还没有一种疫苗被证明对SNV非常有效。在我们的研究中,我们利用IEDB资源中的免疫信息学工具分析了SNV的包膜糖蛋白和核衣壳;以确定B细胞和t细胞最保守和免疫原性的表位。然后将预测表位与MHC-I和MHC-II限制性等位基因的全球人群覆盖率进行比较。在预测的b细胞表位中,糖蛋白和核衣壳的最佳候选表位分别是743CKKYAYPWQT752和271QVDESKVS278。糖蛋白CD8+ T细胞预测表位选择208MTLPVTCFL216和458YTFTSLFSL466。有趣的是,核衣壳的最佳候选表位是25YILSFALPI133和239FLAARCPFL247,它们与MHC I类和II类都具有高亲和力,并且它们在世界范围内对I类和II类等位基因具有良好的种群覆盖率。据我们所知,我们的研究首次预测了B细胞和t细胞表位的混合物,用于设计针对SNV引起的HCPS的有效疫苗
Immunoinformatics Predication and Modelling of a Cocktail of B- and T-cells Epitopes from Envelope Glycoprotein and Nucleocapsid Proteins of Sin Nombre Virus
Sin Nombre virus is a category A pathogen with a reported mortality rate ranging from 30% to 50%. It was responsible for the 2012 Yosemite National Park outbreak. Until now, Specific therapy is not available for the treatment of HCPS caused by SNV. Despite many efforts to develop safe and effective vaccines against SNV, included conventional approaches as well as molecular vaccine approaches, to date there are no vaccines proven to be highly efficacious against SNV. In our study, we analyzed envelope glycoprotein and nucleocapsid of SNV by using immunoinformatics tools housed in IEDB resources; in order to determine the most conserved and immunogenic epitopes for B- and T-cells. Then the predicted epitopes were assessed for the population coverage against the whole world population with the MHC-I and MHC-II restricted alleles. Among predicted epitopes for B-cell, the best candidates for glycoprotein and nucleocapsid were the epitope 743CKKYAYPWQT752 and the epitope 271QVDESKVS278, respectively. For glycoprotein CD8+ T cell predicted epitopes, the epitopes 208MTLPVTCFL216 and 458YTFTSLFSL466 were selected. Interestingly, the best candidates epitopes for nucleocapsid were the epitopes 25YILSFALPI133 and 239FLAARCPFL247 which had high affinity to interact with both MHC classes, I and II, and they had an excellent population coverage for Class I and II alleles throughout the world. To the best of our knowledge, our study for the first time has predicted a cocktail of B- and T-cell epitopes for designing an effective vaccine against HCPS caused by SNV